Alterity Therapeutics Limited (PRNAF)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -12.6 Million | -20.03 Million | -12.33 Million | -17.33 Million | -9.43 Million | -13.95 Million |
| Net Income | -19.12 Million | -13.8 Million | -12.84 Million | -15.3 Million | -10.05 Million | -12.33 Million |
| Depreciation & Amortization | 147.52 Thousand | 102.26 Thousand | 54.21 Thousand | 75.36 Thousand | 112.42 Thousand | 29.69 Thousand |
| Deferred income taxes | - | - | -2.81 Million | -1.88 Million | 12.01 Thousand | -493.01 Thousand |
| Stock-based compensation | 881.95 Thousand | 966.57 Thousand | 1.5 Million | 1.88 Million | -12.01 Thousand | 89.13 Thousand |
| Change in working capital | 5.74 Million | -6.39 Million | 1.76 Million | -4.4 Million | 791.12 Thousand | -1.33 Million |
| Other non-cash items | 6.66 Million | -907.41 Thousand | 61.00 | 2.31 Million | -274.99 Thousand | 89.13 Thousand |
| Investing Cash Flow | -5722.00 | -36.46 Thousand | -89 Thousand | -3000.00 | -16.74 Thousand | -7022.00 |
| Investments in PPE | -5722.00 | -7311.00 | -89 Thousand | -3000.00 | -16.74 Thousand | -7022.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | -29.15 Thousand | - | - | - | - |
| Financing Cash Flow | 9.21 Million | 124.34 Thousand | 16.56 Million | 36.78 Million | 3.98 Million | 12.72 Million |
| Debt repayment | -10.37 Thousand | -59.92 Thousand | -34.51 Thousand | -58.28 Thousand | -89.24 Thousand | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 9.22 Million | 316.67 Thousand | 17.17 Million | 39.23 Million | 4.36 Million | 13.08 Million |
| Other Financing Activities | -918.02 Thousand | -132.41 Thousand | -580.48 Thousand | -2.39 Million | -292.76 Thousand | -362.32 Thousand |
| Accounts receivables | 4.62 Million | -3.94 Million | -447.68 Thousand | -4.21 Million | 4.76 Million | -1.67 Million |
| Accounts payables | - | -1.56 Million | 2.6 Million | 432.9 Thousand | -648.57 Thousand | 662.92 Thousand |
| Inventory | - | 5.5 Million | -2.15 Million | 3.78 Million | -4.11 Million | 1.01 Million |
| Other working capital | -218 Thousand | -6.39 Million | 1.76 Million | -4.4 Million | 791.12 Thousand | -1.33 Million |
| Cash at beginning of period | 15.77 Million | 34.8 Million | 28.11 Million | 9.19 Million | 14.39 Million | 15.23 Million |
| Cash at end of period | 12.63 Million | 15.77 Million | 34.8 Million | 28.11 Million | 9.19 Million | 14.39 Million |
| Capital Expenditure | -5722.00 | -7311.00 | -89 Thousand | -3000.00 | -16.74 Thousand | -7022.00 |
| Effect of forex changes on cash | 260.35 Thousand | 914.94 Thousand | 2.82 Million | -366 Thousand | 262.97 Thousand | 403.87 Thousand |
| Net cash flow / Change in cash | -3.13 Million | -19.03 Million | 6.69 Million | 18.91 Million | -5.2 Million | -835.65 Thousand |
| Free Cash Flow | -12.61 Million | -20.04 Million | -12.42 Million | -17.33 Million | -9.44 Million | -13.96 Million |
| Breakdown | 2024 Q4 | 2024 FY | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -12.61 Million | -19.12 Million | - | -6.5 Million | -3.25 Million | -13.8 Million |
| Depreciation & Amortization | 73.61 Thousand | 147.52 Thousand | - | 73.91 Thousand | 36.95 Thousand | 102.26 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 284.83 Thousand | - | - | 156.14 Thousand | 156.14 Thousand | 966.57 Thousand |
| Change in working capital | 1.56 Million | - | - | 1.62 Million | 754.44 Thousand | -6.39 Million |
| Other non-cash items | 4.57 Million | 6.66 Million | - | 316.51 Thousand | 58.57 Thousand | -907.41 Thousand |
| Investing Cash Flow | -722.00 | -5722.00 | - | -5722.00 | -4000.00 | -36.46 Thousand |
| Investments in PPE | 278.00 | -5722.00 | - | -5722.00 | -4000.00 | -7311.00 |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -1000.00 | - | - | - | - | -29.15 Thousand |
| Financing Cash Flow | 8.16 Million | 9.21 Million | 8.25 Million | 1.05 Million | -17 Thousand | 124.34 Thousand |
| Debt repayment | -10.37 Thousand | - | - | - | - | -59.92 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 8.12 Million | 9.22 Million | 8.92 Million | 1.1 Million | - | 316.67 Thousand |
| Other Financing Activities | -72.02 Thousand | - | -673 Thousand | -54.78 Thousand | -17 Thousand | -132.41 Thousand |
| Accounts receivables | 971.28 Thousand | - | - | 2.68 Million | 1.34 Million | -3.94 Million |
| Accounts payables | - | - | - | 112.93 Thousand | - | -1.56 Million |
| Inventory | - | - | - | - | - | 5.5 Million |
| Other working capital | 597.81 Thousand | - | - | -1.17 Million | -586.28 Thousand | -6.39 Million |
| Cash at beginning of period | 12.32 Million | 15.77 Million | 12.32 Million | 15.77 Million | 15.77 Million | 34.8 Million |
| Cash at end of period | 12.63 Million | 12.63 Million | 18.3 Million | 12.32 Million | 16.7 Million | 15.77 Million |
| Capital Expenditure | 278.00 | -5722.00 | - | -5722.00 | -4000.00 | -7311.00 |
| Effect of forex changes on cash | 39.35 Thousand | - | 307 Thousand | -495 Thousand | 408 Thousand | 914.94 Thousand |
| Net cash flow / Change in cash | 318.45 Thousand | -3.13 Million | 5.98 Million | -3.45 Million | 936 Thousand | -19.03 Million |
| Free Cash Flow | -8.11 Million | -12.61 Million | - | -4.5 Million | 545 Thousand | -20.04 Million |
CITE
UNMA
63MOONS
GPDB
IPL
EMCHF